Targeting epigenetic mechanisms and microRNAs by aspirin and other non steroidal anti-inflammatory agents - Implications for cancer treatment and chemoprevention

Cellular Oncology

Volumn 37, Issue 3, 2014, Pages 167-178

  Yiannakopoulou, Eugenia ^a  

^a UNIVERSITY OF WEST ATTICA   (Greece)

Author keywords

Aspirin; DNA hypermethylation; Epigenetic processes; Global DNA hypomethylation; Histone modification; NSAIDs

Indexed keywords

ACETYLSALICYLIC ACID; ANACARDIC ACID; HISTONE ACETYLTRANSFERASE; HISTONE ACETYLTRANSFERASE P300; HISTONE DEACETYLASE; MICRORNA; NONSTEROID ANTIINFLAMMATORY AGENT; SALICYLIC ACID DERIVATIVE; UNCLASSIFIED DRUG;

ANTIPROLIFERATIVE ACTIVITY; CANCER THERAPY; CANCER TISSUE; CHEMOPROPHYLAXIS; DNA METHYLATION; DOWN REGULATION; EPIGENETICS; GENE ACTIVATION; GENE EXPRESSION; GENE TARGETING; HISTONE ACETYLATION; HISTONE MODIFICATION; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATIENT CODING; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; REVIEW; TUMOR SUPPRESSOR GENE; UPREGULATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; NEOPLASMS;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ASPIRIN; DNA METHYLATION; EPIGENESIS, GENETIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICRORNAS; NEOPLASMS; SALICYLATES;

EID: 84906938826     PISSN: 22113428     EISSN: 22113436     Source Type: Journal    
DOI: 10.1007/s13402-014-0175-7     Document Type: Review

References (67)

1. D. Nebert, G. Zhang, E. Vesell, From human genetics and genomics to pharmacogenetics and pharmacogenomics: past lessons, future directions. Drug Metab Rev 40, 187-224 (2008)
2. P.K. Lo, S. Sukumar, Epigenomics and breast cancer. Pharmacogenomics 9, 1879-1902 (2008)
3. J.G. Martínez, J. Pérez-Escuredo, P. Castro-Santos, C.A. Marcos, J.L. Pendás, M.F. Fraga, Hermsen. M.A. Hypomethylation of LINE-1, and not centromeric SAT-α, is associated with centromeric instability in head and neck squamous cell carcinoma. Cell Oncol 35, 259-67 (2012)
4. S. Babashah, M. Sadeghizadeh, M.R. Tavirani, S. Farivar, Soleimani. M. Aberrant microRNA expression and its implications in the pathogenesis of leukemias. Cell Oncol 35, 317-34 (2012)
5. R. Nagadia, P. Pandit, W.B. Coman, J. Cooper-White, C. Punyadeera, miRNAs in head and neck cancer revisited. Cell Oncol 36, 1-7 (2013)
6. C. Lema, M. Cunningham, MicroRNAs and their implications in toxicological research. Toxicol Lett 198, 100-105 (2010)
7. P.J. Mishra, P.J. Mishra, D. Barenjee, J.R. Bertino, MiRNSPs or MiR polymorphisms, new players in microRNA mediated regulation of the cell. Cell Cycle 7, 853-858 (2008)
8. P.J. Mishra, J.R. Bertino, MicroRNA polymorphisms: the future of pharmacogenomics, molecular epidemiology and personalized medicine. Pharmacogenomics 10, 399-416 (2009)
9. E.D. Wiklund, J. Kjems, S.J. Clark, Epigenetic architecture and miRNA: reciprocal regulators. Epigenomics 6, 823-840 (2010)
10. F.A. Duijkers, R.X. de Menezes, I.J. Goossens-Beumer, D.J. Stumpel, P. Admiraal, R. Pieters, J.P. Meijerink, M.M. van Noesel, Epigenetic drug combination induces genome-wide demethylation and altered gene expression in neuro-ectodermal tumor-derived cell lines. Cell Oncol 36, 351-62 (2013)
11. J.P. Issa, H.M. Kantarjian, Targeting DNA methylation Clin Cancer Res 15, 3938-46 (2009)
12. J. García-Quiroz, J. Camacho, Astemizole: an old anti-histamine as a new promising anti-cancer drug. Anticancer Agents Med Chem 11, 307-14 (2011)
13. C. Zhao, X. Bu, Promoter methylation of tumor-related genes in gastric carcinogenesis. Histol Histopathol 27, 1271-82 (2012)
14. T.M. Brasky, M.R. Bonner, K.B. Moysich, C.B. Ambrosone, J. Nie, M.H. Tao, S.B. Edge, B.V. Kallakury, H.M. Ochs-Balcom, C. Marian, M. Trevisan, P.G. Shields, J.L. Freudenheim, Non steroidal anti-inflammatory drug use (NSAID) and breast cancer risk in the western New York exposures and breast cancer (WEB) study. Cancer Causes Control 9, 1503-1512 (2010)
15. Li, X.; Gao, L.; Cui, Q.; Gary, B.D.; Dyess, D.L.; Taylor, W.; Shevde, L.A.; Samant, R.S.; Dean-Colomb, W.; Piazza, G.A.; Xi, Y. Sulindac inhibits tumor cell invasion by suppressing NF-κB-mediated transcription of microRNAs. Oncogene 31, 4979-4986 (2012)
16. E. Yiannakopoulou, Modulation of lymphangiogenesis: a New target for aspirin and other Nonsteroidal anti-inflammatory agents? a systematic review. J Clin Pharmacol 52, 1749-54 (2011)
17. M. Dovizio, A. Bruno, S. Tacconelli, P. Patrignani, Mode of action of aspirin as a chemopreventive agent. Recent Results Cancer Res 191, 39-65 (2013)
18. J. Worm, P. Guldberg, DNA methylation: an epigenetic pathway to cancer and a promising target for anticancer therapy. J Oral Pathol Med 31, 443-9 (2002)
19. J. Paluszczak, V. Krajka-Kuźniak, W. Baer-Dubowska, The effect of dietary polyphenols on the epigenetic regulation of gene expression in MCF7 breast cancer cells. Toxicol Lett 192, 119-125 (2010)
20. J.L. Medina-Franco, T. Caulfield, Advances in the computational development of DNA methyltransferase inhibitors. Drug Discov Today 16, 418-425 (2011)
21. D. Kuck, N. Singh, F. Lyko, J.L.Medina-Franco, Novel and selective DNA methyltransferase inhibitors: Docking-based virtual screening and experimental evaluation. Bioorg Med Chem 18, 822-829 (2010)
22. J. Yoo, J.L. Medina Franco, Trimethylaurintricarboxylic acid inhibits human DNA methyltransferase 1: insights from enzymatic and molecular modeling studies. J Mol Model 18, 1583-1589 (2012)
23. M.R. Pan, H.C. Chang, L.Y. Chuang, W.C. Hung, The nonsteroidal anti-inflammatory drug NS398 reactivates SPARC expression via promoter demethylation to attenuate invasiveness of lung cancer cells. Exp Biol Med (Maywood) 233, 456-462 (2008)
24. T. Tahara, T. Shibata, M. Nakamura, H. Yamashita, D. Yoshioka, M. Okubo, N. Maruyama, T. Kamano, Y. Kamiya, H. Fujita, M. Nagasaka, M. Iwata, K. Takahama, M. Watanabe, I. Hirata, T. Arisawa, Chronic aspirin use suppresses CDH1 methylation in human gastric mucosa. Dig Dis Sci 55, 54-9 (2010)
25. T. Tahara, T. Shibata, H. Yamashita, M. Nakamura, D. Yoshioka, M. Okubo, I. Hirata, T. Arisawa, Chronic nonsteroidal anti-inflammatory drug (NSAID) use suppresses multiple CpG islands hyper methylation (CIHM) of tumor suppressor genes in the human gastric mucosa. Cancer Sci 100, 1192-1197 (2009)
26. M.L. Slattery, R.K. Wolff, J. Herrick, B.J. Caan, W. Samowitz, Tumor markers and rectal cancer: support for an inflammation-related pathway. Int J Cancer 125, 1698-1704 (2009)
27. M.L. Slattery, K. Curtin, C. Sweeney, T.R. Levin, J. Potter, R.K. Wolff, H. Albertsen, W.S. Samowitz, Diet and lifestyle factor associations with CpG island methylator phenotype and BRAF mutations in colon cancer. Int J Cancer 120, 656-663 (2007)
28. E.I. Heath, M.I. Canto, S. Piantadosi, E. Montgomery, W.M. Weinstein, J.G. Herman, A.J. Dannenberg, V.W. Yang, A.O. Shar, E. Hawk, A.A. Forastiere, Chemoprevention for Barrett's esophagus trial research group. Secondary chemoprevention of Barrett's esophagus with celecoxib: results of a randomized trial. J. Natl. Cancer Risk 99, 545-557 (2007)
29. K. Wallace, M.V. Grau, A.J. Levine, L. Shen, R. Hamdan, X. Chen, J. Gui, R.W. Haile, E.L. Barry, D. Ahnen, G. McKeown-Eyssen, J.A. Baron, J.P. Issa, Association between folate levels and CpG Island hypermethylation in normal colorectal mucosa. Cancer Prev Res (Phila) 3, 1552-1564 (2010)
30. J.C. Figueiredo, M.V. Grau, K. Wallace, A.J. Levine, L. Shen, R. Hamdan, X. Chen, R.S. Bresalier, G. McKeown-Eyssen, R.W. Haile, J.A. Baron, J.P. Issa, Global DNA hypomethylation (LINE-1) in the normal colon and lifestyle characteristics and dietary and genetic factors. Cancer Epidemiol Biomarkers Prev 18, 1041-1049 (2009)
31. L. Tao, W. Wang, P.M. Kramer, R.A. Lubet, V.E. Steele, M.A. Pereira, Modulation of DNA hypomethylation as a surrogate endpoint biomarker for chemoprevention, of colon cancer. Mol Carcinogen 39, 79-842 (2004)
32. M.A. Pereira, L. Tao, W. Wang, Y. Li, A. Umar, V.E. Steele, Modulation by celecoxib and difluoromethylornithine of the methylation of DNA and the estrogen receptor-alpha gene in rat colon tumors. Carcinogenesis 25, 1917-1923 (2004)
33. R. Shen, L. Tao, Y. Xu, S. Chang, J. Van Brocklyn, J.X. Gao, Reversibility of aberrant global DNA and estrogen receptor-alpha gene methylation distinguishes colorectal precancer fromcancer. Int J Clin Exp Pathol 2, 21-23 (2009)
34. R.M. Eglen, T. Reisine, Screening for compounds that modulate epigenetic regulation of the transcriptome: an overview. J Biomol Screen 16, 1137-1152 (2011)
35. A. Mai, L. Altucci, Epi-drugs to fight cancer: from chemistry to cancer treatment, the road ahead. Int J Biochem Cell Biol 41, 199-213 (2009)
36. P. Kamble, K. Selvarajan, C. Aluganti Narasimhulu, M. Nandave, S. Parthasarathy, Aspirin may promote mitochondrial biogenesis via the production of hydrogen peroxide and the induction of Sirtuin1/PGC-1α genes. Eur J Pharmacol 699, 55-61 (2013)
37. F. Di Renzo, G. Cappelletti, M.L. Broccia, E. Giavini, E. Menegola, The inhibition of embryonic histone deacetylases as the possible mechanism accounting for axial skeletal malformations induced by sodium salicylate. Toxicol Sci 104, 397-404 (2008)
38. J. Sonnemann, I. Hüls, M. Sigler, C.D. Palani, T.T. le Hong, U. Völker, H.K. Kroemer, J.F. Beck, Histone deacetylase inhibitors and aspirin interact synergistically to induce cell death in ovarian cancer cells. Oncol Rep 20, 219-224 (2008)
39. K. Deckmann, F. Rörsch, G. Geisslinger, S. Grösch, Dimethylcelecoxib induces an inhibitory complex consisting of HDAC1/NF-κB(p65)RelA leading to transcriptional downregulation of mPGES-1 and EGR1. Cell Signal 24, 460 -467 (2012)
40. H. Yoshioka, T. Watanabe, T.E. Eling, Nonsteroidal antiinflammatory drug-activated gene (NAG-1/GDF15) expression is increased by the histone deacetylase inhibitor trichostatin A. J Biol Chem 283, 33129-33137 (2008)
41. S. Marimuthu, R.S. Chivukula, L.F. Alfonso, M. Moridani, F.K. Hagen, G.J. Bhat, Aspirin acetylates multiple cellular proteins in HCT-116 colon cancer cells: Identification of novel targets. Int J Oncol 39, 1273-1283 (2011)
42. S.B. Jung, C.S. Kim, A. Naqvi, T. Yamamori, I. Mattagajasingh, T.A. Hoffman, M.P. Cole, A. Kumar, J.S. Dericco, B.H. Jeon, K. Irani, Histone deacetylase 3 antagonizes aspirin-stimulated endothelial nitric oxide production by reversing aspirin-induced lysine acetylation of endothelial nitric oxide synthase. Circ Res 107, 877-87 (2010)
43. J. Tan, B. Chen, L. He, Y. Tang, Z. Jiang, G. Yin, J.Wang, X. Jiang, Anacardic acid (6-pentadecylsalicylic acid) induces apoptosis of prostate cancer cells through inhibition of androgen receptor and activation of p53 signaling. Chin J Cancer Res 24, 275-83 (2012)
44. B. Sung, M.K. Pandey, K.S. Ahn, T. Yi, M.M. Chaturvedi, M. Liu, B.B. Aggarwal, Anacardic acid (6-nonadecyl salicylic acid), an inhibitor of histone acetyltransferase, suppresses expression of nuclear factor-kappaB-regulated gene products involved in cell survival, proliferation, invasion, and inflammation through inhibition of the inhibitory subunit of nuclear factor-kappaBalpha kinase, leading to potentiation of apoptosis. Blood 111, 4880-4891 (2008)
45. Y. Sun, X. Jiang, S. Chen, B.D. Price, Inhibition of histone acetyltransferase activity by anacardic acid sensitizes tumor cells to ionizing radiation. FEBS Lett 580, 4353-4356 (2006)
46. Y. Kim, K. Kim, D. Park, E. Lee, H. Lee, Y.S. Lee, J. Choe, Y.M. Kim, D. Jeoung, DNA methyl transferase I acts as a negative regulator of allergic skin inflammation. Mol Immunol 53, 1-14 (2013)
47. A. Koornneef, K. Rindermann, C. Gatz, C.M. Pieterse, Histone modifications do not play a major role in salicylate-mediated suppression of jasmonate-induced PDF1.2 gene expression. Commun Integr Biol 1, 143-5 (2008)
48. T. Tanaka, A. Kurose, H.D. Halicka, X. Huang, F. Traganos, Z. Darzynkiewicz, Nitrogen oxide-releasing aspirin induces histone H2AX phosphorylation, ATM activation and apoptosis preferentially in S-phase cells: involvement of reactive oxygen species. Cell Cycle 5, 1669-74 (2006)
49. M. Yanokura, K. Banno, Y. Kobayashi, I. Kisu, A. Ueki, A. Ono, K. Masuda, H. Nomura, A. Hirasawa, N. Susumu, D. Aoki, MicroRNA and endometrial cancer: Roles of small RNAs in human tumors and clinical applications (Review). Oncol Lett 1, 935-940 (2010)
50. F. Lan, X. Yue, L. Han, Z. Shi, Y. Yang, P. Pu, Z. Yao, C. Kang, Genome-wide identification of TCF7L2/TCF4 target miRNAs reveals a role for miR-21 in Wnt-driven epithelial cancer. Int J Oncol 40, 519-526 (2012)
51. Y. Chen, W. Liu, T. Chao, Y. Zhang, X. Yan, Y. Gong, B. Qiang, J. Yuan, M. Sun, X. Peng, MicroRNA-21 down-regulates the expression of tumor suppressor PDCD4 in human glioblastoma cell T98G. Cancer Lett 272, 197-205 (2008)
52. F. Meng, R. Henson, H. Wehbe-Janek, K. Ghoshal, S.T. Jacob, T. Patel, MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology 133, 647-658 (2007)
53. Q. Yao, H. Xu, Q.Q. Zhang, H. Zhou, L.H. Qu, MicroRNA-21 promotes cell proliferation and down-regulates the expression of programmed cell death 4 (PDCD4) in HeLa cervical carcinoma cells. Biochem Biophys Res Commun 388, 539-542 (2009)
54. Sicard, F.; Gayral, M.; Lulka, H.; Buscail, L.; Cordelier, P. Targeting miR-21 for the Therapy of Pancreatic Cancer. Mol Ther, 2013, doi:10.1038/mt.2013.35
55. Y. Saito, H. Suzuki, H. Imaeda, J. Matsuzaki, K. Hirata, H. Tsugawa, S. Hibino, Y. Kanai, H. Saito, T. Hibi, The tumor suppressor microRNA-29c is downregulated and restored by celecoxib in human gastric cancer cells. Int J Cancer 132, 1751-1760 (2013)
56. W.C. Chen, M.S. Lin, Y.L. Ye, H.J. Gao, Z.Y. Song, X.Y. Shen, microRNA expression pattern and its alteration following celecoxib intervention in human colorectal cancer. Exp Ther Med 3, 1039-1048 (2012)
57. J. Tan, L. Fan, J.J.Mao, B. Chen, L. Zheng, T. Zhang, T. Li, J. Duan, Y. Duan, Z. Jin, W. Kuang, Restoration of miR-34a in p53 deficient cells unexpectedly promotes the cell survival by increasing NFκB activity. J Cell Biochem 113, 2903-8 (2012)
58. E.D. Eliseeva, V. Valkov, M. Jung, M.O. Jung, Characterization of novel inhibitors of histone acetyltransferases. Mol Cancer Ther 6, 2391-2398 (2007)
59. A.R. Cyr, F.E. Domann, The redox basis of epigenetic modifications: from mechanisms to functional consequences. Antioxid Redox Signal 15, 551-589 (2011)
60. R.H. Dowen, M. Pelizzola, R.J. Schmitz, R. Lister, J.M. Dowen, J.R. Nery, J.E. Dixon, J.R. Ecker, Widespread dynamic DNA methylation in response to biotic stress. Proc Natl Acad Sci U S A 109, E2183-E2191 (2012)
61. K. Schrör, Pharmacology and cellular/molecular mechanisms of action of aspirin and non-aspirin NSAIDs in colorectal cancer. Best Pract Res Clin Gastroenterol 25, 473-484 (2011)
62. E.C. Yiannakopoulou, E. Tiligada, Protective effect of salicylates against hydrogen peroxide stress in yeast. J Appl Microbiol 106, 903-908 (2009)
63. M.C. de Andrés, K. Imagawa, K. Hashimoto, A. Gonzalez, H.I. Roach, M.B. Goldring, R.O. Oreffo, Loss of methylation in CpG sites in the NF-κB enhancer elements of inducible nitric oxide synthase is responsible for gene induction in human articular chondrocytes. Arthritis Rheum 65, 732-742 (2013)
64. Fata, J.E.; Debnath, S.; Jenkins, E.C. Jr; Fournier, M.V. Nongenomic Mechanisms of PTEN Regulation. Int. J. Cell Biol., 2012, 379685
65. K.K. Wu, Transcription-based COX-2 inhibition: a therapeutic strategy. Thromb Haemost 96, 417-422 (2006)
66. D.A. Dixon, F.F. Blanco, A. Bruno, P. Patrignani, Mechanistic aspects of COX-2 expression in colorectal neoplasia. Recent Results Cancer Res 191, 7-37 (2013)
67. S. Fu, R. Kurzrock, Development of curcumin as an epigenetic agent. Cancer 116, 4670 -4676 (2010)